There are currently 434 active clinical trials seeking participants for Breast Cancer research studies. The states with the highest number of trials for Breast Cancer participants are California, Ohio, Illinois and Michigan.
Improving Genetic Counseling for BRCA+ Mothers
Recruiting
Genetic counseling and testing for hereditary breast cancer may reveal that you, and possibly your blood relatives, are at increased risk for the disease across the lifespan. This includes biological children, both male and female. We do not yet know the best ways to educate mothers who have a risk gene (are BRCA+) about whether, when, and how to share genetic information with their children or manage their thoughts and feelings. The purpose of this study is to help mothers make more informed ch... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: MedStar Georgetown University Hospital, Washington, District of Columbia
Conditions: Breast Cancer
STOP-HER2: Stopping Trastuzumab in HER2+ MBC
Recruiting
This study is being done to see if anti-HER2 treatment be safely stopped in patients with HER2-positive metastatic breast cancer (MBC) that have had exceptional response to treatment. Exceptional response" is considered as cancer progression being controlled for three years or more since starting anti-HER2 treatment.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Mayo Clinic Hospital Arizona, Phoenix, Arizona +12 locations
Conditions: Breast Cancer, Metastatic Breast Cancer, HER2-positive Breast Cancer
Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
Recruiting
Investigators propose a double-blind, placebo-controlled trial evaluating the use of the use of Suvorexant in breast cancer survivors on selective estrogen receptor modulators or aromatase inhibitors with sleep disturbance to assess the impact on insomnia symptoms and quality of life. Breast cancer survivors have an increased risk of insomnia for which Suvorexant has the has the potential ability to impact to improve sleep related outcomes and cancer survivorship outcomes. Breast cancer survivor... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: MUSC Department of Family Medicine, Charleston, South Carolina
Conditions: Breast Cancer, Insomnia
EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
Recruiting
The purpose of this research study is to evaluate the outcomes of two standard of care group exercise regimens to increase muscle mass in women who have been treated with breast cancer.
Gender:
FEMALE
Ages:
Between 20 years and 89 years
Trial Updated:
09/20/2024
Locations: Allegheny General Hospital, Pittsburgh, Pennsylvania
Conditions: Breast Cancer, Breast Carcinoma in Situ, Breast Cancer Female
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer
Recruiting
This research study is looking to see whether the combination of Dostarlimab and Niraparib plus Radiation Therapy (RT) is safe and effective in participants with metastatic triple negative breast cancer. The names of the study treatment involved in this study are: * Dostarlimab * Niraparib * Radiation Therapy (RT), which is given per standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/19/2024
Locations: Sibley Memorial Hospital, Washington, District of Columbia +3 locations
Conditions: Breast Cancer, Triple Negative Breast Cancer
Investigating the Use of TaVNS to Treat Insomnia in Individuals with Breast Cancer (taVNS-insomnia-BC)
Recruiting
In the present study, the investigators aim to investigate feasibility of utilizing noninvasive neuromodulation, specifically taVNS, as a nonpharmacologic approach to address insomnia in patients with stage I-IV breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/17/2024
Locations: UAB Lakeshore Collaborative (WHARF), Birmingham, Alabama +1 locations
Conditions: Breast Cancer, Insomnia
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Recruiting
This purpose of this study is to test if talazoparib is safe and evaluate its response to advanced breast cancer associated with mutation of gene called PALB.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/14/2024
Locations: Stanford University, Stanford, California
Conditions: Breast Cancer, Advanced Breast Cancer
Improving Care for Rural Patients With Solid Tumors
Recruiting
This study will assess if the CARES (Cancer Advocacy, Resources, Education and Support) intervention improves time to start of treatment after diagnosis and time to treatment completion for solid tumors (ex: lung, head, neck, thyroid, cervical, breast, bladder, colon, and rectal cancers) in rural patients.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
09/13/2024
Locations: University of Colorado Hospital, Aurora, Colorado +11 locations
Conditions: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Cervical Cancer, Breast Cancer, Bladder Cancer, Colon Cancer, Rectum Cancer
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
Recruiting
The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: Baylor Medicine, Houston, Texas +1 locations
Conditions: Breast Cancer, Axillary Lymph Nodes
Intra-Operative Radiation Registry
Recruiting
This registry trial is designed to track the local control rates and side effects of IORT, which will be implemented for women who are suitable PBI per the latest ASTRO guidelines.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/10/2024
Locations: Montefiore Medical Center - Moses Campus, Bronx, New York
Conditions: Breast Cancer
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer
Recruiting
The purpose of this study is to determine the impact of pre-operative cryoablation, and immune checkpoint inhibition (ICI) on on 3-year Event Free Survival (EFS), in women with residual hormone receptor negative, HER2-negative ("triple negative") resectable breast cancer after taxane-based neoadjuvant chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
09/09/2024
Locations: Cedars Sinai Medical Center, Los Angeles, California +3 locations
Conditions: Breast Cancer
YES Study - Newly Diagnosed/Metastatic Intervention
Recruiting
This research study is being done to monitor common symptoms and behavior, and to provide supportive care information and peer support, as well as research opportunities for young women ages of 18-39 years old who have been diagnosed with stage 0-IV stage breast cancer using a web-based portal (YES), built for smartphones, tablets, and computers.
Gender:
FEMALE
Ages:
Between 18 years and 39 years
Trial Updated:
09/09/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Breast Cancer, Symptom, Behavioral